CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives…
SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global…
Investment from Prominent Blues Health Plans Spotlights Growing Public Health ImperativeTAMPA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- GuideWell and…
-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart…
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in…
FORT LAUDERDALE, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"),…
MISSISSAUGA, Ontario, May 02, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for…
MORRISTOWN, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and…
Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1…